Stay updated with breaking news from Patrickt Ogara. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For an all-comer population with any impairment of LV function, an interarterial shunt device missed the primary endpoint in RELIEVE-HF, but benefit was seen with LVEF less than 40%.
Explore special articles published online first to coincide with presentations at AHA American Heart Association's Annual Scientific Session.
TTE will remain the “workhorse” for routine assessment, but CMR’s value deserves further consideration, editorialists agree.
December 23, 2020 Guidelines for the management of valvular heart disease (VHD) have been refreshed by the American College of Cardiology and American Heart Association—the first full revision since 2014. Most salient among the changes is the inclusion of the pivotal low-risk TAVR trials that led to US Food and Drug Administration approval for that indication last fall. With Catherine M. Otto, MD (University of Washington, Seattle), and Rick A. Nishimura, MD (Mayo Clinic, Rochester, MN), as co-chairs, the multisociety-produced document was published online last week in both Circulation and...
E-Mail DALLAS and WASHINGTON, Dec. 17, 2020 -- Options to treat heart valve disease are expanding, allowing patients to avoid surgery when possible, according to a new joint clinical practice guideline from the American College of Cardiology and the American Heart Association. The new "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease" published today in the AHA's flagship journal Circulation and in the Journal of the American College of Cardiology. About half of all people ages 65 and older have some form of valvular heart disease. If left undiagnosed or u...